Literature DB >> 23980056

The effect of letrozole with misoprostol for medical termination of pregnancy on the expression of steroid receptors in the placenta.

Vivian Chi-Yan Lee1, Jing Gao, Kai-Fai Lee, Ernest Hung-Yu Ng, William Shu-Biu Yeung, Pak-Chung Ho.   

Abstract

STUDY QUESTION: What is the effect of letrozole on the expression of steroid receptors in the placentae in cases of termination of pregnancies? SUMMARY ANSWER: The expression of estrogen receptor-α (ERα) and progesterone receptor (PR) transcripts, as well as ERα protein, in placentae was suppressed by letrozole pretreatment in second trimester termination of pregnancy. WHAT IS KNOWN ALREADY: There have been no data in the literature on the effect of letrozole in termination of human pregnancies. STUDY DESIGN, SIZE, DURATION: This study is part of a clinical randomized trial in which 50 subjects were recruited and 44 placentae were collected. PARTICIPANTS/MATERIALS, SETTING,
METHODS: Women (n = 50) requesting second trimester abortion between 12 and 20 gestational weeks were randomized to receive either letrozole or placebo pretreatment for 3 days before administration of vaginal misoprostol. Placentae were collected from both groups of women after the abortion. Total RNA from the frozen placenta samples was extracted and subjected to real-time RT-PCR analysis of ERα and estrogen receptor-β (ERβ), PR and glucocorticoid receptor (GR) transcripts. Immunohistochemical studies of ERα, ERβ, PR and GR expression, as well as Ki67 and PCNA staining for proliferation, were performed. TUNEL assays were performed to determine the extent of apoptosis. MAIN RESULTS AND THE ROLE OF CHANCE: Real-time RT-PCR demonstrated that the median ERα {3.900 [95% confidence interval (CI): -0.643-8.443] in the letrozole group versus 4.714 (95% CI: 1.776-7.652) in the control group; P = 0.005} and the median PR [0.701 (95% CI: 0.333-1.069) in the letrozole group versus 1.774 (95% CI: 1.07-2.478) in the control group; P = 0.003] were significantly lower in the letrozole group compared with the control group. Furthermore, ERα protein levels, in both syncytiotrophoblasts and cytotrophoblasts but not in villous stromal cells, were significantly reduced [H-score of 113 (95% CI: 103-119) in the letrozole group versus 217 (95% CI: 214-290) in the control group, in syncytiotrophoblasts; 100 (95% CI: 98-105) in the letrozole group versus 210 (95% CI: 200-286) in the control group, in cytotrophoblasts; P = 0.004], while the expression levels of ERβ, PR, GR, PCNA, Ki67 and TUNEL were not significantly different between the two groups. LIMITATIONS, REASONS FOR CAUTION: Only the placentae from the second trimester termination of pregnancy were collected in this study. Information from first trimester terminations is still lacking. WIDER IMPLICATIONS OF THE
FINDINGS: The results shed some light on the mechanism of action of letrozole pretreatment in termination of pregnancies. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by the GRF/RGC and CRCG grants of the University of Hong Kong. TRIAL REGISTRATION NUMBER: HKClinicalTrials.com with trial number HKCTR-695.

Entities:  

Keywords:  letrozole pretreatment; misoprostol; second trimester; steroid receptors; termination of pregnancy

Mesh:

Substances:

Year:  2013        PMID: 23980056     DOI: 10.1093/humrep/det345

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  2 in total

1.  Evaluation of Different Doses of the Aromatase Inhibitor Letrozole for the Treatment of Ectopic Pregnancy and Its Effect on Villous Trophoblastic Tissue.

Authors:  Mohamed Ali Alabiad; Warda M M Said; Abdalla Hassan Gad; Mustafa Taha Abdelfattah Sharaf ElDin; Dina Ahmed Khairy; Mai Ahmed Gobran; Amany Mohamed Shalaby; Walaa Samy; Ahmed Ahmed Abdelsameea; Ahmed Ismail Heraiz
Journal:  Reprod Sci       Date:  2022-06-14       Impact factor: 2.924

2.  Letrozole vs. Placebo Pretreatment in the Medical Management of First Trimester Missed Miscarriage: a Randomized Controlled Trial.

Authors:  Haitham A Torky; Heba Marie; ElSayed ElDesouky; Samy Gebreel; Osama Raslan; Asem A Moussa; Ali M Ahmad; Eman Zain; Mohamed N Mohsen
Journal:  Geburtshilfe Frauenheilkd       Date:  2018-01-22       Impact factor: 2.915

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.